When you understand prostate cancer aggressiveness, you will be able to better determine an accurate treatment plan. One thing you will likely learn is that aggressive treatment isn’t always the best treatment. 40-50% of patient with low-risk prostate cancer could be candidates for active surveillance. Whereas, only 20-30% of patients with intermediate or high-risk cancer could require more aggressive treatment.
Fortunately, Prolaris testing can provide you with new and unique information about prostate cancer aggressiveness. This means you can make more informed decisions about what treatment plan is right for your patient.